{"id":"W1668902290","doi":"10.1182/blood.v124.21.4559.4559","title":"Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Bosutinib; Nilotinib; Dasatinib; Medicine; Internal medicine; Imatinib; Gastroenterology; Imatinib mesylate; Myeloid leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002119977,0.0005079497,0.001230733,0.0002891259,0.0002765073,0.0008049457,0.0003936214,0.0005497058,0.0009909917],"category_scores_gemma":[0.0008713254,0.0002210357,0.001119807,0.0003747883,0.0002492316,0.0005312116,0.0002536843,0.001512089,0.0002916552],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005059919,"about_ca_system_score_gemma":0.0006247521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006823003,"about_ca_topic_score_gemma":0.002308302,"domain_scores_codex":[0.9996021,0.000202092,0.00003541969,0.00004190209,0.0000576372,0.00006078535],"domain_scores_gemma":[0.9992802,0.0001393706,0.0002102503,0.00003124048,0.00005815445,0.0002808192],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3564303,0.02711155,0.1601129,0.001486566,0.003519315,0.001268656,0.0006285185,0.002148814,0.03919221,0.0002231635,0.00969052,0.3981876],"study_design_scores_gemma":[0.2159614,0.4741403,0.2798384,0.0002387222,0.003213776,0.002260464,0.0002667171,0.004402396,0.006085843,0.0002181943,0.01329589,0.00007795943],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991823,0.006031375,0.0001917855,0.0003168571,0.00006652741,0.0003358069,0.0004898563,0.00002708123,0.0007176705],"genre_scores_gemma":[0.9940267,0.002927716,0.0004709056,0.0006168596,0.0001434543,0.0002334195,0.001150958,0.000007509501,0.0004224969],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002119977,"threshold_uncertainty_score":0.01121163,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01291187195401717,"score_gpt":0.2859074742347657,"score_spread":0.2729956022807485,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}